iRay Group

iRay Group CROIC

The Cash Return on Invested Capital (CROIC) of iRay Group (688301.SS) as of Oct 16, 2026 is -3.93 %. In the previous year, Cash Return on Invested Capital (CROIC) was -13.21 % — a change of -70.27% (higher).

CROIC

-3.93 %

YoY

-70.27%

Last updated:

Cash Return on Invested Capital (CROIC) of iRay Group is 2025 -3.93 % . Cash Return on Invested Capital (CROIC) of iRay Group was 2024 -13.21 % . It decreases by -70.27% higher compared to the previous year.

The iRay Group CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-8.36 CNY
Jan 1, 2019
-1.92 CNY
Jan 1, 2020
9.07 CNY
Jan 1, 2021
1.81 CNY
Jan 1, 2022
-7.55 CNY
Jan 1, 2023
-23.54 CNY
Jan 1, 2024
-13.21 CNY
Jan 1, 2025
-3.93 CNY
The iRay Group CROIC history
YEARCROICYoY
-3.93 %-70.27%
-13.21 %-43.88%
-23.54 %+211.96%
-7.55 %-517.04%
1.81 %-80.04%
9.07 %-572.43%
-1.92 %-77.04%
-8.36 %-132.61%
25.62 %+134.39%
10.93 %-69.61%
35.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iRay Group Stock analysis

What does iRay Group do? iRay Group, operating under the ticker symbol 688301.SS and identified by ISIN CNE1000042V8, is a prominent entity within the Chinese healthcare sector. Headquartered in Shanghai, the company has established itself as a significant player in the medical technology industry, specifically focusing on the development and manufacturing of advanced digital imaging solutions. The organization went public on September 18, 2020, marking a pivotal moment in its corporate history and allowing it to expand its operational capabilities on a broader scale. As of the latest available data, iRay Group employs a workforce of 1,237 full-time employees, reflecting its substantial operational footprint and commitment to human capital in driving technological innovation. The core business of the company revolves around the research, development, production, and sale of digital X-ray detectors, which are critical components in modern medical diagnostic equipment. These detectors are engineered to provide high-resolution imaging, enabling healthcare professionals to make accurate and timely diagnoses. The product portfolio of iRay Group is diverse and tailored to meet various clinical and industrial needs. Key product lines include the universal radio frequency series, which offers versatile imaging solutions for general diagnostic purposes. Additionally, the company manufactures specialized breast series detectors designed specifically for mammography, ensuring high sensitivity and image clarity for early detection of breast abnormalities. The radiotherapy series further expands the company's reach into therapeutic applications, providing essential imaging support for radiation treatment planning and monitoring. Beyond the medical sector, the technology developed by iRay Group finds application in industrial non-destructive testing and security inspection fields. This diversification highlights the robustness of their detector technology, which can be adapted for inspecting materials integrity in manufacturing or screening for security threats. The company maintains a comprehensive distribution network that serves both the domestic market within China and international markets overseas. This global reach underscores the competitive quality of their products and the company's strategic focus on expanding its presence in the worldwide healthcare and industrial technology sectors. By leveraging its expertise in digital X-ray technology, iRay Group continues to contribute to advancements in medical diagnostics and industrial safety, positioning itself as a key innovator in the health care industry. iRay Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iRay Group stock

Cash Return on Invested Capital (CROIC) of iRay Group is -3.93 % in 2025.

Cash Return on Invested Capital (CROIC) of iRay Group changed from -13.21 % to -3.93 %, representing a -70.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) iRay Group since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s iRay Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — iRay Group

All Key Metrics — iRay Group